Suppressive Effects of 1,4-dihydroxy-2-naphthoic Acid Administration on Bone Resorption

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2009 Oct 9

PMID 19813044

Citations 4

Authors

M Matsubara

E Yamachika

H Tsujigiwa

N Mizukawa

T Ueno

J Murakami

N Ishida

Y Kaneda

N Shirasu

S Takagi

Affiliations

Soon will be listed here.

Abstract

Summary: The main component of the metabolic by-products of fermentation by Propionibacterium freudenreichii ET-3 is 1,4-dihydroxy-2-naphthoic acid (DHNA), which has a naphthoquinone skeleton, as in vitamin K2. This study showed that DHNA improved bone mass reduction with osteoporosis model mice caused by FK506.

Introduction: Growth of the intestinal bacterium Lactobacillus bifidus is specifically facilitated by DHNA. The present study used osteoporosis model mice to investigate the effects of DHNA on bone remodeling.

Methods: FK506, an immunosuppressant, was used to prepare osteoporosis model mice. Thirty mice were divided into three groups: FK group, FK+DHNA group, and control group. In the FK group, FK506 was administered to induce bone mass reduction. In the FK-DHNA group, FK506 and DHNA were administered concurrently to observe improvements in bone mass reduction. To ascertain systemic and local effects of DHNA, we investigated systemic pathological changes in colon, kidney function and cytokine dynamics, and morphological and organic changes in bone and osteoclast dynamics as assessed by culture experiments.

Results: Compared to the FK group without DHNA, colon damage and kidney dysfunction were milder for FK+DHNA group, and production of inflammatory cytokines (interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha) was more suppressed. Furthermore, compared to the group without DHNA, histological analyses and radiography showed that bone resorption was suppressed for the DHNA group. Culture experiments using osteoclasts from murine bone marrow showed osteoclast suppression for the DHNA group compared to the group without DHNA.

Conclusion: These results show that DHNA has some effects for improving bone mass reduction caused by FK506.

Citing Articles

Detection of 1,4-dihydroxy-2-naphthoic Acid from commercial makgeolli products.

Eom J, Kwon S, Moon G Prev Nutr Food Sci. 2014; 17(1):83-6.

PMID: 24471067 PMC: 3866769. DOI: 10.3746/pnf.2012.17.1.083.

Lactobacillus fermentation enhances the inhibitory effect of Hwangryun-haedok-tang in an ovariectomy-induced bone loss.

Shim K, Kim T, Ha H, Lee K, Cho C, Kim H BMC Complement Altern Med. 2013; 13:106.

PMID: 23680047 PMC: 3694040. DOI: 10.1186/1472-6882-13-106.

Hwangryun-Haedok-Tang Fermented with Lactobacillus casei Suppresses Ovariectomy-Induced Bone Loss.

Shim K, Kim T, Ha H, Cho C, Kim H, Seo D Evid Based Complement Alternat Med. 2012; 2012:325791.

PMID: 23082080 PMC: 3468024. DOI: 10.1155/2012/325791.

Methyl-1-hydroxy-2-naphthoate, a novel naphthol derivative, inhibits lipopolysaccharide-induced inflammatory response in macrophages via suppression of NF-κB, JNK and p38 MAPK pathways.

Zhang J, Jin H, Wang G, Yu P, Wu S, Zhu Z Inflamm Res. 2011; 60(9):851-9.

PMID: 21667204 DOI: 10.1007/s00011-011-0345-2.

References

Cohen A, Shane E . Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int. 2003; 14(8):617-30. DOI: 10.1007/s00198-003-1426-z. View

Kirino S, Fukunaga J, Ikegami S, Tsuboi H, Kimata M, Nakata N . Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. J Bone Miner Metab. 2004; 22(6):554-60. DOI: 10.1007/s00774-004-0523-1. View

Shane E, Addesso V, Namerow P, McMahon D, Lo S, Staron R . Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004; 350(8):767-76. DOI: 10.1056/NEJMoa035617. View

Goto T, Kino T, Hatanaka H, OKUHARA M, Kohsaka M, Aoki H . FK 506: historical perspectives. Transplant Proc. 1991; 23(6):2713-7. View

Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba M . Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001; 12(6):484-92. DOI: 10.1007/s001980170094. View

Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masuda J, Takaki K . Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition. 2005; 22(1):76-81. DOI: 10.1016/j.nut.2005.04.013. View

Crawford B, Kam C, Pavlovic J, Byth K, Handelsman D, Angus P . Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006; 144(4):239-48. DOI: 10.7326/0003-4819-144-4-200602210-00005. View

Gordon C, Binello E, LeBoff M, Wohl M, Rosen C, Colin A . Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis. Osteoporos Int. 2006; 17(5):783-90. PMC: 3206625. DOI: 10.1007/s00198-005-0058-x. View

Fukunaga J, Yamaai T, Yamachika E, Ishiwari Y, Tsujigiwa H, Sawaki K . Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. Bone. 2004; 34(3):425-31. DOI: 10.1016/j.bone.2003.05.003. View

10.

Ke H, Huai Q . Structures of calcineurin and its complexes with immunophilins-immunosuppressants. Biochem Biophys Res Commun. 2003; 311(4):1095-102. DOI: 10.1016/s0006-291x(03)01537-7. View

11.

Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M . Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest. 1999; 104(3):229-37. PMC: 408412. DOI: 10.1172/JCI5705. View

12.

Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S . Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000; 191(2):275-86. PMC: 2195746. DOI: 10.1084/jem.191.2.275. View

13.

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, MINAGUCHI H . A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int. 2002; 13(12):971-9. DOI: 10.1007/s001980200135. View

14.

Kaneko T, Mori H, Iwata M, Meguro S . Growth stimulator for bifidobacteria produced by Propionibacterium freudenreichii and several intestinal bacteria. J Dairy Sci. 1994; 77(2):393-404. DOI: 10.3168/jds.S0022-0302(94)76965-4. View

15.

Okada Y, Tsuzuki Y, Miyazaki J, Matsuzaki K, Hokari R, Komoto S . Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut. 2005; 55(5):681-8. PMC: 1856113. DOI: 10.1136/gut.2005.070490. View

16.

Chang J, Green L, Beitz J . Renal failure with the use of zoledronic acid. N Engl J Med. 2003; 349(17):1676-9. DOI: 10.1056/NEJM200310233491721. View

17.

Rodino M, Shane E . Osteoporosis after organ transplantation. Am J Med. 1998; 104(5):459-69. DOI: 10.1016/s0002-9343(98)00081-3. View

18.

Isawa K, Hojo K, Yoda N, Kamiyama T, Makino S, Saito M . Isolation and identification of a new bifidogenic growth stimulator produced by Propionibacterium freudenreichii ET-3. Biosci Biotechnol Biochem. 2002; 66(3):679-81. DOI: 10.1271/bbb.66.679. View

19.

Jimi E, Nakamura I, Duong L, Ikebe T, Takahashi N, Rodan G . Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res. 1999; 247(1):84-93. DOI: 10.1006/excr.1998.4320. View

20.

Mrvos R, Hodgman M, Krenzelok E . Tacrolimus (FK 506) overdose: a report of five cases. J Toxicol Clin Toxicol. 1997; 35(4):395-9. DOI: 10.3109/15563659709043372. View